skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study

Abstract

Purpose: To assess the relationship between the dose to the bulb of the penis and the risk of impotence in men treated on Radiation Therapy Oncology Group (RTOG) 9406. Methods and materials: Men enrolled on a Phase I/II dose-escalation study, RTOG 9406, who were reported to be potent at entry and evaluable (n = 158) were selected for inclusion. Follow-up evaluations were scheduled every 3, 4, and 6 months for the first, second, and the third through fifth years, then annually. At each follow-up visit an assessment of potency status was made. Penile structures were defined by a single observer blinded to the potency status, using Web-based, on-line software. The dosimetry for penile structures was calculated at the Quality Assurance Center at Washington University and provided to RTOG Statistical Headquarters to determine whether there was a relationship between dose and impotence. Results: Patients whose median penile dose was {>=}52.5 Gy had a greater risk of impotence compared with those receiving <52.5 Gy (p = 0.039). In a multivariate analysis neither age, the dose to the prostate, nor the use of hormonal therapy correlated with the risk of impotence. Conclusions: Dose to the bulb of the penis seems to be associatedmore » with the risk of radiation-induced impotence.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [5];  [5];  [6]
  1. University of California San Francisco, San Francisco, CA (United States)
  2. Radiation Therapy Oncology Group, Philadelphia, PA (United States)
  3. Washington University, St. Louis, MO (United States)
  4. 3D Quality Assurance Center at Washington University St. Louis, MO (United States)
  5. University of Texas M.D. Anderson Cancer Center, Houston, TX (United States)
  6. Massachusetts General Hospital, Boston MA (United States)
Publication Date:
OSTI Identifier:
20630972
Resource Type:
Journal Article
Journal Name:
International Journal of Radiation Oncology, Biology and Physics
Additional Journal Information:
Journal Volume: 60; Journal Issue: 5; Other Information: DOI: 10.1016/j.ijrobp.2004.05.026; PII: S0360-3016(04)00826-0; Copyright (c) 2004 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); Journal ID: ISSN 0360-3016
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; COMPUTER CODES; DOSIMETRY; EVALUATION; PATIENTS; PROSTATE; QUALITY ASSURANCE; RADIATION DOSES; RADIOTHERAPY

Citation Formats

Roach, Mack, Winter, Kathryn, Michalski, Jeffrey M, Cox, James D, Purdy, James A, Bosch, Walter, Xiao, Lin, and Shipley, William S. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study. United States: N. p., 2004. Web. doi:10.1016/j.ijrobp.2004.05.026.
Roach, Mack, Winter, Kathryn, Michalski, Jeffrey M, Cox, James D, Purdy, James A, Bosch, Walter, Xiao, Lin, & Shipley, William S. Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study. United States. https://doi.org/10.1016/j.ijrobp.2004.05.026
Roach, Mack, Winter, Kathryn, Michalski, Jeffrey M, Cox, James D, Purdy, James A, Bosch, Walter, Xiao, Lin, and Shipley, William S. 2004. "Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study". United States. https://doi.org/10.1016/j.ijrobp.2004.05.026.
@article{osti_20630972,
title = {Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: Findings from a prospective, multi-institutional, phase I/II dose-escalation study},
author = {Roach, Mack and Winter, Kathryn and Michalski, Jeffrey M and Cox, James D and Purdy, James A and Bosch, Walter and Xiao, Lin and Shipley, William S},
abstractNote = {Purpose: To assess the relationship between the dose to the bulb of the penis and the risk of impotence in men treated on Radiation Therapy Oncology Group (RTOG) 9406. Methods and materials: Men enrolled on a Phase I/II dose-escalation study, RTOG 9406, who were reported to be potent at entry and evaluable (n = 158) were selected for inclusion. Follow-up evaluations were scheduled every 3, 4, and 6 months for the first, second, and the third through fifth years, then annually. At each follow-up visit an assessment of potency status was made. Penile structures were defined by a single observer blinded to the potency status, using Web-based, on-line software. The dosimetry for penile structures was calculated at the Quality Assurance Center at Washington University and provided to RTOG Statistical Headquarters to determine whether there was a relationship between dose and impotence. Results: Patients whose median penile dose was {>=}52.5 Gy had a greater risk of impotence compared with those receiving <52.5 Gy (p = 0.039). In a multivariate analysis neither age, the dose to the prostate, nor the use of hormonal therapy correlated with the risk of impotence. Conclusions: Dose to the bulb of the penis seems to be associated with the risk of radiation-induced impotence.},
doi = {10.1016/j.ijrobp.2004.05.026},
url = {https://www.osti.gov/biblio/20630972}, journal = {International Journal of Radiation Oncology, Biology and Physics},
issn = {0360-3016},
number = 5,
volume = 60,
place = {United States},
year = {Wed Dec 01 00:00:00 EST 2004},
month = {Wed Dec 01 00:00:00 EST 2004}
}